Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1

Journal of Clinical Pathology

Volumn 56, Issue 10, 2003, Pages 758-763

  Cunha, K S G ^a   Barboza, E P ^a   Da Fonseca, E C ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NEUROFIBROMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; CHILD; FEMALE; GROWTH DISORDERS; GROWTH HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEUROFIBROMA; NEUROFIBROMATOSIS 1; RECEPTORS, SOMATOTROPIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0141918869     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.10.758     Document Type: Article

References (35)

1. Neurofibromatosis, NIH Consens Statement 1987;6:1-19.
2. Friedman JM, Gutmann DH, Maccollin M, et al. Neurofibromatosis. Phenotype, natural history and pathogenesis, 3rd ed. Baltimore: The Johns Hopkins University Press, 1999.
3. Gorlin RJ, Cohen MM, Levin LS, et al. Syndromes of the head and neck, 3rd ed. Oxford: Oxford University Press, 1990.
4. Cotran R, Kumar V, Robbins S. Robbins patologia estrutural e funcional, 5th ed. Rio de Janeiro: Guanabara Koogan, 1996.
5. Heim RA, Kam-Morgan LN, Binnie CG, et al. Distribution of 13 truncating mutations in the neurofibromatosis 1 gene. Hum Mol Genet 1995;4:975-81.
6. Kitano Y, Okamoto E, Saito K, et al. Effects of several growth factors on cultured neurofibroma cells. J Dermatol Sci 1992;3:137-44.
7. Vogel KS, Klesse LJ, Velasco-Miguel S, et al. Mouse tumor model for neurofibromatosis type 1. Science 1999;286:2176-9.
8. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three nf1 patients. Science 1990;249:181-6.
9. Cawthon RM, Weiss R, Xu G, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990;62:193-201.
10. Shearer P, Parham D, Kovnar E. Neurofibromatosis type I and malignancy: review of 32 pediatric cases treated at a single institution. Med Pediatr Oncol 1994;22:78-83.
11. Geller M, Bonalumi Filho A. Neurofibromatose. In: Carakushansky G, ed. Doenças genéticas em pediatria. Rio de janeiro: Guanabara-Koogan, 2001:377-90.
12. Martuza RL, Maclaughlin DT, Ojemann RG. Specific estradiol binding in schawnnomas, meningiomas and neurofibromas. Neurosurgery 1981;9:665-71.
13. Chaudhuri PK, Walker MJ, Das Gupta TK, et al. Steroid receptors in tumors of nerve sheath origin. J Surg Oncol 1982;20:205-6.
14. Reed ML, Jacoby RA. Cutaneous neuroanatomy and neuropathology. Normal nerves, neural-crest derivates, and benign neural neoplasms in the skin. Am J Dermatopathol 1983:5:335-62.
15. Billestrup N, Hansen JA, Hansen LH, et al. Molecular mechanism of growth hormone signaling. Endocr J 1998;45:s41-5.
16. Carter-Su C, Rui L, Stofega MR. SH2-B and SIRP: JAK2 binding proteins that modulate the actions of growth hormone. Recent Prog Horm Res 2000;55:293-311.
17. Withdrawn
18. Emerman JT, Leahy M, Gout PW. Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 1985;17:421-4.
19. Garcia-Caballero T, Mertani HM, Lambert A, et al. Increased expression of growth hormone and prolactin receptors in hepatocellular carcinomas. Endocrine 2000;12:265-71.
20. Ginarte M, Garcia-Callabero T, Fernandez-Redondo V, et al. Expression of growth hormone receptor in benign and malignant cutaneous proliferative entities. J Cutan Pathol 2000;27:276-82.
21. Kaulsay KK, Zhu T, Bennett W, et al. The effects of autocrine human growth hormone (hgh) on human mammary carcinoma cell behavior are mediated via the hgh receptor. Endocrinology 2001;142:767-77.
22. Lincoln DT, Sinowatz F, Temmim-Baker L, et al. Growth hormone receptor expression in the nucleus and cytoplasm of normal and neoplastic cells. Histochem Cell Biol 1998;109:141-59.
23. Andrews GS. Growth hormone and malignancy. J Clin Pathol 1983;36:935-7.
24. Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 1980;12:71-9.
25. Barzilay J, Heatley GJ, Cushing GW. Benign and malignant tumors in patients with acromegaly. Arch Intern Med 1991;151:1629-32.
26. Bengtsson BA, Edén S, Ernest I, et al. Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988;223:327-35.
27. Ratner RE, Hare JW. Association of acromegaly and chondrosarcoma. South Med J 1983,76:1181-2.
28. Aktan M, Tanakol R, Nalcaci M, et al. Leukemia in a patient treated with growth hormone. Endocr J 2000;47:471-3.
29. Watanabe S, Mizuno S, Oshima LH, et al. Leukemia and other malignancies among GH users. J Pediatr Endocrinol 1993;6:99-108.
30. British Prostate Study Group. Evaluation of plasma hormone concentrations in relation to clinical staging in patients with prostate cancer. Br J Urol 1979;51:382-9.
31. Saenger P. Growth hormone in von Recklinghausen's disease: reckless or recommended? J Pediatr 1998;133:172-4.
32. Declue JE, Heffelfinger S, Benvenuto G, et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 2000;105:1233-41.
33. Sherman LS, Tit R, Rosenbaum T, et al. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma schwann cells but not fibroblasts. J Biol Chem 2000;275:30740-5.
34. Lobie PE, Breipohl W. Growth hormone receptor expression in the rat gastrointestinal tract. Endocrinology 1990;126:299-306.
35. Lobie PE, Mertani H, Morel G, et al. Receptor-mediated nuclear translocation of growth hormone. J Biol Chem 1994;269:21330-9.